Oxygen Biotherapeutics setting up for monster session after Phyxius deal

Shares of Oxygen Biotherapeutics (OXBT) are building on Monday's AH gains, and are now up some 77% premarket.

After the bell Monday, the company outlined a major management shakeup and also announced the acquisition of levosimendan, a Phase 3 asset. 

More on the deal here

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs